1
|
Sex/Gender- and Age-Related Differences in β-Adrenergic Receptor Signaling in Cardiovascular Diseases. J Clin Med 2022; 11:jcm11154280. [PMID: 35893368 PMCID: PMC9330499 DOI: 10.3390/jcm11154280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 07/15/2022] [Accepted: 07/22/2022] [Indexed: 11/17/2022] Open
Abstract
Sex differences in cardiovascular disease (CVD) are often recognized from experimental and clinical studies examining the prevalence, manifestations, and response to therapies. Compared to age-matched men, women tend to have reduced CV risk and a better prognosis in the premenopausal period. However, with menopause, this risk increases exponentially, surpassing that of men. Although several mechanisms have been provided, including sex hormones, an emerging role in these sex differences has been suggested for β-adrenergic receptor (β-AR) signaling. Importantly, β-ARs are the most important G protein-coupled receptors (GPCRs), expressed in almost all the cell types of the CV system, and involved in physiological and pathophysiological processes. Consistent with their role, for decades, βARs have been considered the first targets for rational drug design to fight CVDs. Of note, β-ARs are seemingly associated with different CV outcomes in females compared with males. In addition, even if there is a critical inverse correlation between β-AR responsiveness and aging, it has been reported that gender is crucially involved in this age-related effect. This review will discuss how β-ARs impact the CV risk and response to anti-CVD therapies, also concerning sex and age. Further, we will explore how estrogens impact β-AR signaling in women.
Collapse
|
2
|
Effects of chronic mirabegron treatment on metabolic and cardiovascular parameters as well as on atherosclerotic lesions of WHHL rabbits with high-fructose high-fat diet-induced insulin resistance. Eur J Pharmacol 2022; 921:174870. [DOI: 10.1016/j.ejphar.2022.174870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 02/28/2022] [Accepted: 03/02/2022] [Indexed: 11/23/2022]
|
3
|
Saunders SL, Hutchinson DS, Britton FC, Liu L, Markus I, Sandow SL, Murphy TV. Effect of β 1 /β 2 -adrenoceptor blockade on β 3 -adrenoceptor activity in the rat cremaster muscle artery. Br J Pharmacol 2021; 178:1789-1804. [PMID: 33506492 DOI: 10.1111/bph.15398] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 01/19/2021] [Accepted: 01/19/2021] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND AND PURPOSE The physiological role of vascular β3 -adrenoceptors is not fully understood. Recent evidence suggests cardiac β3 -adrenoceptors are functionally effective after down-regulation of β1 /β2 -adrenoceptors. The functional interaction between the β3 -adrenoceptor and other β-adrenoceptor subtypes in rat striated muscle arteries was investigated. EXPERIMENTAL APPROACH Studies were performed in cremaster muscle arteries isolated from male Sprague-Dawley rats. β-adrenoceptor expression was assessed through RT-PCR and immunofluorescence. Functional effects of β3 -adrenoceptor agonists and antagonists and other β-adrenoceptor ligands were measured using pressure myography. KEY RESULTS All three β-adrenoceptor subtypes were present in the endothelium of the cremaster muscle artery. The β3 -adrenoceptor agonists mirabegron and CL 316,243 had no effect on the diameter of pressurized (70 mmHg) cremaster muscle arterioles with myogenic tone, while the β3 -adrenoceptor agonist SR 58611A and the nonselective β-adrenoceptor agonist isoprenaline caused concentration-dependent dilation. In the presence of β1/2 -adrenoceptor antagonists nadolol (10 μM), atenolol (1 μM) and ICI 118,551 (0.1 μM) both mirabegron and CL 316,243 were effective in causing vasodilation and the potency of SR 58611A was enhanced, while responses to isoprenaline were inhibited. The β3 -adrenoceptor antagonist L 748,337 (1 μM) inhibited vasodilation caused by β3 -adrenoceptor agonists (in the presence of β1/2 -adrenoceptor blockade), but L 748,337 had no effect on isoprenaline-induced vasodilation. CONCLUSION AND IMPLICATIONS All three β-adrenoceptor subtypes were present in the endothelium of the rat cremaster muscle artery, but β3 -adrenoceptor mediated vasodilation was only evident after blockade of β1/2 -adrenoceptors. This suggests constitutive β1/2 -adrenoceptor activity inhibits β3 -adrenoceptor function in the endothelium of skeletal muscle resistance arteries.
Collapse
Affiliation(s)
- Samantha L Saunders
- Physiology, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - Dana S Hutchinson
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Fiona C Britton
- Department of Biomedical Sciences, School of Dental Medicine, University of Nevada, Las Vegas, Las Vegas, Nevada, USA
| | - Lu Liu
- Pharmacology, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - Irit Markus
- Pharmacology, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - Shaun L Sandow
- Physiology, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia.,Biomedical Science, School of Health and Sports Science, University of the Sunshine Coast, Maroochydore, Queensland, Australia
| | - Timothy V Murphy
- Physiology, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| |
Collapse
|
4
|
Abstract
Cardiovascular disease (CVD) is a public health concern, and the third cause of death worldwide. Several epidemiological studies and experimental approaches have demonstrated that consumption of polyphenol-enriched fruits and vegetables can promote cardioprotection. Thus, diet plays a key role in CVD development and/or prevention. Physiological β-adrenergic stimulation promotes beneficial inotropic effects by increasing heart rate, contractility and relaxation speed of cardiomyocytes. Nevertheless, chronic activation of β-adrenergic receptors can cause arrhythmias, oxidative stress and cell death. Herein the cardioprotective effect of human metabolites derived from polyphenols present in berries was assessed in cardiomyocytes, in response to chronic β-adrenergic stimulation, to disclose some of the underlying molecular mechanisms. Ventricular cardiomyocytes derived from neonate rats were treated with three human bioavailable phenolic metabolites found in circulating human plasma, following berries' ingestion (catechol-O-sulphate, pyrogallol-O-sulphate, and 1-methylpyrogallol-O-sulphate). The experimental conditions mimic the physiological concentrations and circulating time of these metabolites in the human plasma (2 h). Cardiomyocytes were then challenged with the β-adrenergic agonist isoproterenol (ISO) for 24 h. The presence of phenolic metabolites limited ISO-induced mitochondrial oxidative stress. Likewise, phenolic metabolites increased cell beating rate and synchronized cardiomyocyte beating population, following prolonged β-adrenergic receptor activation. Finally, phenolic metabolites also prevented ISO-increased activation of PKA-cAMP pathway, modulating Ca2+ signalling and rescuing cells from an arrhythmogenic Ca2+ transients' phenotype. Unexpected cardioprotective properties of the recently identified human-circulating berry-derived polyphenol metabolites were identified. These metabolites modulate cardiomyocyte beating and Ca2+ transients following β-adrenergic prolonged stimulation.
Collapse
|
5
|
Yang HQ, Wang LP, Gong YY, Fan XX, Zhu SY, Wang XT, Wang YP, Li LL, Xing X, Liu XX, Ji GS, Hou T, Zhang Y, Xiao RP, Wang SQ. β
2
-Adrenergic Stimulation Compartmentalizes β
1
Signaling Into Nanoscale Local Domains by Targeting the C-Terminus of β
1
-Adrenoceptors. Circ Res 2019; 124:1350-1359. [DOI: 10.1161/circresaha.118.314322] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Hua-Qian Yang
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Li-Peng Wang
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Yun-Yun Gong
- Beijing Advanced Innovation Center for Biomedical Engineering, and School of Biological Science and Medical Engineering, Beihang University, Beijing, China (Y.-Y.G)
| | - Xue-Xin Fan
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Si-Yu Zhu
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Xiao-Ting Wang
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Yu-Pu Wang
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Lin-Lin Li
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Xin Xing
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Xiao-Xiao Liu
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Guang-Shen Ji
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - TingTing Hou
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Yan Zhang
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Rui-Ping Xiao
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| | - Shi-Qiang Wang
- From the State Key Lab of Membrane Biology, College of Life Sciences and Institute of Molecular Medicine, Peking University, Beijing, China (H.-Q.Y., L.-P.W., X.-X.F., S.-Y.Z., X.-T.W., Y.-P.W., L.-L.L., X.X., X.-X.L., G.-S.J., T.T.H., Y.Z., R.-P.X., S.-Q.W.)
| |
Collapse
|
6
|
Zuo G, Ren X, Qian X, Ye P, Luo J, Gao X, Zhang J, Chen S. Inhibition of JNK and p38 MAPK-mediated inflammation and apoptosis by ivabradine improves cardiac function in streptozotocin-induced diabetic cardiomyopathy. J Cell Physiol 2018; 234:1925-1936. [PMID: 30067872 DOI: 10.1002/jcp.27070] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Accepted: 06/25/2018] [Indexed: 01/01/2023]
Abstract
Inflammation plays a critical role in the development of diabetic cardiomyopathy (DCM), which has been identified as a major predisposing factor for heart failure in diabetic patients. Previous studies indicated that ivabradine (a specific agent for heart rate [HR] reduction) has anti-inflammatory properties, but its role in DCM remains unknown. This study investigated whether ivabradine exerts a therapeutic effect in DCM. C57BL/6J mice were injected intraperitoneally with streptozotocin (STZ) to induce diabetes; then administered with ivabradine or saline (control). After 12 weeks, the surviving mice were analyzed to determine the cardioprotective effect of ivabradine against DCM. Although treatment with ivabradine did not affect blood glucose levels, it attenuated tumor necrosis factor-α, interleukin-1β, and interleukin-6 messenger RNA (mRNA) expression, inhibited c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) activation, reduced histological abnormalities, myocardial apoptosis and collagen deposition, and improved cardiac function in the diabetic mice. Interestingly, the anti-inflammatory and antiapoptotic properties of ivabradine, but not its inhibitory effect on JNK and p38 MAPK, were observed in high-glucose-cultured neonatal rat ventricular cardiomyocytes. Attenuating inflammation and apoptosis via intramyocardial injection of lentiviruses carrying short hairpin RNA targeting JNK and p38 MAPK validated that the anti-inflammatory and antiapoptotic effects of ivabradine were partly attributed to JNK and p38 MAPK inactivation in diabetic mice. In summary, these data indicate that ivabradine-mediated improvement of cardiac function in STZ-induced diabetic mice may be partly attributed to inhibition of JNK/p38 MAPK-mediated inflammation and apoptosis, which is dependent on the reduction in HR.
Collapse
Affiliation(s)
- Guangfeng Zuo
- Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Xiaomin Ren
- Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Xuesong Qian
- Department of Cardiology, Zhangjiagang First People's Hospital, Zhangjiagang, China
| | - Peng Ye
- Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.,Department of General Clinical Research Center, Nanjing First Hospital, Nanjing, China
| | - Jie Luo
- Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.,Department of Basic Medicine, Key Laboratory of Cardiovascular Disease and Molecular Intervention, Nanjing Medical University, Nanjing, China
| | - Xiaofei Gao
- Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.,Department of General Clinical Research Center, Nanjing First Hospital, Nanjing, China
| | - Junjie Zhang
- Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Shaoliang Chen
- Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| |
Collapse
|
7
|
Montaudon E, Dubreil L, Lalanne V, Jagu B, Toumaniantz G, Thorin C, Henrion D, Desfontis JC, Martignat L, Mallem MY. Effects of long-term active immunization with the second extracellular loop of human β 1- or β 3-adrenoceptors in thoracic aorta and mesenteric arteries in Lewis rats. Vascul Pharmacol 2016; 87:129-138. [PMID: 27620808 DOI: 10.1016/j.vph.2016.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2016] [Revised: 08/18/2016] [Accepted: 09/05/2016] [Indexed: 10/21/2022]
Abstract
OBJECTIVE To evaluate whether active immunization producing β1- or β3-antibodies (β1-ABs and β3-ABs) detected in sera of patients with dilated cardiomyopathies has deleterious effects on vascular reactivity in Lewis rat thoracic aorta (TA) and small mesenteric arteries (SMA). DESIGN AND METHOD Lewis rats were immunized for 6months with peptidic sequences corresponding to the second extracellular loop of β1- and β3-adrenoceptors (ARs). During the immunization, systolic blood pressure (SBP) was monitored using the tail cuff method. The vascular reactivity of immunized rats was assessed by ex vivo studies on SMA and TA using various β-AR agonists, phenylephrine and KCl. RESULTS The immunizations producing functional β1-ABs and β3-ABs did not affect the SBP. However, in TA from β1-AR-immunized rats, the relaxations mediated by dobutamine and salbutamol were significantly impaired in comparison with adjuvant rats whereas nebivolol-induced relaxation was not modified. Moreover, phenylephrine and KCl-mediated contractions were enhanced in these rats. In contrast, immunization with β3-AR peptide led to the increase of relaxations induced by dobutamine in TA but did not change those induced by salbutamol and nebivolol. Surprisingly, in SMA from both rats immunized with β1- or β3-peptides, relaxations induced by the various β-agonists were not changed whereas phenylephrine and KCl-mediated contractions were impaired. CONCLUSIONS Our study shows that β1- and β3-ABs can affect vascular reactivity. β1-ABs would have a pathogenic action whereas β3-ABs would have a beneficial effect on aorta reactivity.
Collapse
Affiliation(s)
- E Montaudon
- LUNAM University, Oniris, UPSP 5304 of Animal Pathophysiology and Functional Pharmacology, Atlanpôle La Chantrerie, BP 40706, 44307 Nantes, France
| | - L Dubreil
- LUNAM University, Oniris, INRA UMR U703, PanTHER, Atlanpôle La Chantrerie, BP 40706, 44307 Nantes, France
| | - V Lalanne
- LUNAM University, Oniris, UPSP 5304 of Animal Pathophysiology and Functional Pharmacology, Atlanpôle La Chantrerie, BP 40706, 44307 Nantes, France
| | - B Jagu
- LUNAM University, INSERM, UMR 1087/CNRS 6291 Institut du Thorax, F44007 Nantes, France
| | - G Toumaniantz
- LUNAM University, INSERM, UMR 1087/CNRS 6291 Institut du Thorax, F44007 Nantes, France
| | - C Thorin
- LUNAM University, Oniris, UPSP 5304 of Animal Pathophysiology and Functional Pharmacology, Atlanpôle La Chantrerie, BP 40706, 44307 Nantes, France
| | - D Henrion
- LUNAM University, CNRS UMR 6214, INSERM U1083, F-49000 Angers, France
| | - J-C Desfontis
- LUNAM University, Oniris, UPSP 5304 of Animal Pathophysiology and Functional Pharmacology, Atlanpôle La Chantrerie, BP 40706, 44307 Nantes, France
| | - L Martignat
- LUNAM Univsersity, Oniris, UPSP, Sanitary Safety in Biotechnologies of the Reproduction, La Chantrerie, BP 40706, 44307 Nantes, France
| | - M Y Mallem
- LUNAM University, Oniris, UPSP 5304 of Animal Pathophysiology and Functional Pharmacology, Atlanpôle La Chantrerie, BP 40706, 44307 Nantes, France.
| |
Collapse
|
8
|
β3-adrenoceptor impacts apoptosis in cultured cardiomyocytes via activation of PI3K/Akt and p38MAPK. ACTA ACUST UNITED AC 2016; 36:1-7. [DOI: 10.1007/s11596-016-1533-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Revised: 11/29/2015] [Indexed: 12/25/2022]
|
9
|
Montaudon E, Dubreil L, Lalanne V, Vermot Des Roches M, Toumaniantz G, Fusellier M, Desfontis JC, Martignat L, Mallem M. Cardiac effects of long-term active immunization with the second extracellular loop of human β1- and/or β3-adrenoceptors in Lewis rats. Pharmacol Res 2015; 100:210-9. [DOI: 10.1016/j.phrs.2015.08.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Revised: 06/28/2015] [Accepted: 08/07/2015] [Indexed: 12/23/2022]
|
10
|
Atorvastatin prevents sepsis-induced downregulation of myocardial β1-adrenoceptors and decreased cAMP response in mice. Shock 2015; 41:406-12. [PMID: 24430540 DOI: 10.1097/shk.0000000000000138] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Impaired cardiac β-adrenoceptor signaling is an important cause of sepsis-induced myocardial depression in man and experimental animals. We examined the effect of atorvastatin (ATR) pretreatment on myocardial β1-adrenoceptor (β1-AR) expressions and post-receptor signaling in a mouse model of sepsis (cecal ligation and puncture [CLP]). After 20 ± 2 h of surgery, hearts were isolated for the measurement of left ventricular functions (left ventricular developed pressure, dp/dt(max) and dp/dt(min)) using Langendorff setup. Western blot was used to determine β1-AR and G protein-coupled receptor kinase 2 protein expressions. Real-time polymerase chain reaction was done to determine β1-AR mRNA expression. Atorvastatin prevented sepsis-induced decrease in left ventricular functions, such as left ventricular developed pressure (CLP 75.90 ± 0.53 vs. ATR 100.24 ± 1.64 mmHg), dp/dtmax (CLP 3,742 ± 71 vs. ATR 4,291 ± 88 mmHg/s), and dp/dt(min) (CLP -1,010 ± 24 vs. ATR -1,346 ± 84 mmHg/s). Associated with functional impairments, sepsis decreased both myocardial β1-AR protein and mRNA expressions by 52% ± 9% and 62% ± 7%, respectively. However, ATR treatment of CLP mice (ATR) preserved β1-AR protein (96% ± 11%) and mRNA (88% ± 14%) expressions comparable to sham-operated level. Furthermore, it not only attenuated sepsis-induced decrease in basal cardiac adenosine 3',5'-cyclic monophosphate content (CLP 1.30 ± 0.27 vs. ATR 6.30 ± 0.67 pmol/mg protein), but also prevented its refractoriness to dobutamine stimulation (CLP 1.72 ± 0.27 vs. ATR 10.83 ± 1.37 pmol/mg protein). Atorvastatin also inhibited sepsis-induced increase in cardiac G protein-coupled receptor kinase 2 protein expression (CLP 1.73 ± 0.18-fold vs. ATR 1.10 ± 0.18-fold), protein kinase A activity (CLP 1.12 ± 0.14 vs. ATR 0.66 ± 0.08 U/mg protein) and plasma catecholamines (CLP 138 ± 22 vs. ATR 59 ± 2 pg/mL). In conclusion, ATR seems to improve left ventricular functions in vitro through the preservation of β(1)-AR signaling in sepsis.
Collapse
|
11
|
Walsh SK, Hector EE, Andréasson AC, Jönsson-Rylander AC, Wainwright CL. GPR55 deletion in mice leads to age-related ventricular dysfunction and impaired adrenoceptor-mediated inotropic responses. PLoS One 2014; 9:e108999. [PMID: 25275556 PMCID: PMC4183508 DOI: 10.1371/journal.pone.0108999] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Accepted: 09/05/2014] [Indexed: 01/25/2023] Open
Abstract
G protein coupled receptor 55 (GPR55) is expressed throughout the body, and although its exact physiological function is unknown, studies have suggested a role in the cardiovascular system. In particular, GPR55 has been proposed as mediating the haemodynamic effects of a number of atypical cannabinoid ligands; however this data is conflicting. Thus, given the incongruous nature of our understanding of the GPR55 receptor and the relative paucity of literature regarding its role in cardiovascular physiology, this study was carried out to examine the influence of GPR55 on cardiac function. Cardiac function was assessed via pressure volume loop analysis, and cardiac morphology/composition assessed via histological staining, in both wild-type (WT) and GPR55 knockout (GPR55−/−) mice. Pressure volume loop analysis revealed that basal cardiac function was similar in young WT and GPR55−/− mice. In contrast, mature GPR55−/− mice were characterised by both significant ventricular remodelling (reduced left ventricular wall thickness and increased collagen deposition) and systolic dysfunction when compared to age-matched WT mice. In particular, the load-dependent parameter, ejection fraction, and the load-independent indices, end-systolic pressure-volume relationship (ESPVR) and Emax, were all significantly (P<0.05) attenuated in mature GPR55−/− mice. Furthermore, GPR55−/− mice at all ages were characterised by a reduced contractile reserve. Our findings demonstrate that mice deficient in GPR55 exhibit maladaptive adrenergic signalling, as evidenced by the reduced contractile reserve. Furthermore, with age these mice are characterised by both significant adverse ventricular remodelling and systolic dysfunction. Taken together, this may suggest a role for GPR55 in the control of adrenergic signalling in the heart and potentially a role for this receptor in the pathogenesis of heart failure.
Collapse
Affiliation(s)
- Sarah K. Walsh
- Institute for Health & Wellbeing Research, Robert Gordon University, Riverside East, Aberdeen, United Kingdom
| | - Emma E. Hector
- Institute for Health & Wellbeing Research, Robert Gordon University, Riverside East, Aberdeen, United Kingdom
| | | | | | - Cherry L. Wainwright
- Institute for Health & Wellbeing Research, Robert Gordon University, Riverside East, Aberdeen, United Kingdom
- * E-mail:
| |
Collapse
|
12
|
Petersen LH, Needham SL, Burleson ML, Overturf MD, Huggett DB. Involvement of β3-adrenergic receptors in in vivo cardiovascular regulation in rainbow trout (Oncorhynchus mykiss). Comp Biochem Physiol A Mol Integr Physiol 2013; 164:291-300. [DOI: 10.1016/j.cbpa.2012.11.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2012] [Revised: 10/30/2012] [Accepted: 11/01/2012] [Indexed: 01/10/2023]
|
13
|
Abstract
Catecholamines play a key role in the regulation of cardiovascular function, classically through ß(1/2)-adrenoreceptors (AR) activation. After ß(3)-AR cloning in the late 1980s, convincing evidence for ß(3)-AR expression and function in cardiovascular tissues recently initiated a reexamination of their involvement in the pathophysiology of cardiovascular diseases. Their upregulation in diseased cardiovascular tissues and resistance to desensitization suggest they may be attractive therapeutic targets. They may substitute for inoperant ß(1/2)-AR to mediate vasodilation in diabetic or atherosclerotic vessels. In cardiac ventricle, their contractile effects are functionally antipathetic to those of ß(1/2)-AR; in normal heart, ß(3)-ARs may mediate a moderate negative inotropic effect, but in heart failure, it may protect against adverse effects of excessive catecholamine stimulation by action on excitation-contraction coupling, electrophysiology, or remodelling. Thus, prospective studies in animals and patients at different stages of heart failure should lead to identify the best therapeutic window to use ß(3)-AR agonists and/or antagonists.
Collapse
|
14
|
Kandavar R, Higashi Y, Chen W, Blackstock C, Vaughn C, Sukhanov S, Sander GE, Roffidal LE, Delafontaine P, Giles TD. The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension. JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION : JASH 2011; 5:161-5. [PMID: 21251896 PMCID: PMC3141281 DOI: 10.1016/j.jash.2010.11.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2010] [Revised: 11/11/2010] [Accepted: 11/15/2010] [Indexed: 11/29/2022]
Abstract
This study sought to determine if metoprolol succinate ER (MET), and nebivolol (NEB), a β1-AR with increased bioavailability of nitric oxide (NO), would have differing effects on plasma asymmetric dimethylarginine concentration in hypertensives. It was hypothesized that NEB, a β1-AR antagonist and β3-AR agonist with NO-releasing properties, and MET, only a β1-AR antagonist, would have different effects on plasma asymmetric dimethylarginine (ADMA) concentration. Forty-one hypertensive subjects randomly received either 50 mg of MET (n = 19) or 5 mg of NEB (n = 22) for 4 weeks followed by 100 mg MET and 10 mg NEB for 4 weeks. ADMA and insulin-like growth factor-1 (IGF-1) were measured by enzyme-linked immunosorbent assay kit; endothelial progenitor cells were estimated using fluorescein-labeled monoclonal antibody to KDR and CD133 receptors; arterial augmentation index was measured by radial tonometry. Baseline systolic/diastolic blood pressure was 155.1 ± 18.7/85.3 ± 12.5 mm Hg for MET subjects and 157.6 ± 20.7/87.1 ± 14.0 mm Hg for NEB subjects. Baseline ADMA was 0.32 ± 0.123 μmol/L in the MET group and 0.4035 ± 0.1378 in the NEB group. ADMA increased 44.78% and 72% in the MET group at weeks 4 and 8 (P < .05 for both), respectively, without increase in the NEB group. At week 8, augmentation index was increased in the MET group (P < .05). IGF-1 and endothelial progenitor cells were unchanged by treatment. Plasma ADMA and augmentation index are increased in a dose-dependent fashion by MET but not with NEB.
Collapse
Affiliation(s)
- Ramprasad Kandavar
- Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Current World Literature. Curr Opin Cardiol 2011; 26:71-8. [DOI: 10.1097/hco.0b013e32834294db] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Abstract
This themed section of BJP includes 11 reviews on the biology of G-protein coupled receptors (GPCRs) and the drug targets that these present, 21 research papers on the pharmacology of a range of GPCRs and Commentaries on four of the papers. Areas reviewed include molecular interactions, particular in respect of hetero-dimerisation between receptors and other membrane-located proteins and other key signalling molecules including cAMP and G12/13 proteins and recently de-orphanised receptors including the Neuromedins U & S and the Free Fatty Acid receptors FFA2 & FFA3. The research papers cover the pharmacology of a range of agents acting at GPCRs, including adrenoceptors, purinoceptors, 5HT, opioid, cannabinoid & PAR-2 receptors. A group of papers is concerned with the interesting and rapidly developing pharmacology of drugs acting at beta(2)-adrenoceptors. The reach of GPCRs is illustrated by the range of physiological systems and therapeutic applications involved, including pain, cancer, cardiovascular, gastrointestinal, visual and respiratory and central nervous systems.
Collapse
|